IgA肾病的生物标志物和靶向性新疗法  

Biomarkers and new targeted therapies for IgA nephropathy

作　　者：朱梦莲 王丽 樊均明 ZHU Menglian;WANG Li;FAN Junming(Department of Nephrologythe Affiliated T.C.M Hospital of Southwest Medical University,Luzhou 646000,Sichuan Province,China;Research Center of Integrated Chinese and Western Medicine,the Affiliated T.C.M Hospital of Southwest Medical University,Luzhou 646000,Sichuan Province,China;Chengdu Medical College)

机构地区：[1]西南医科大学附属中医医院肾病内科,四川泸州646000 [2]西南医科大学附属中医医院中西医结合研究中心,四川泸州646000 [3]成都医学院

出　　处：《西南医科大学学报》2019年第1期90-92,共3页Journal of Southwest Medical University

基　　金：国家自然科学基金(81641025);四川省第一批科技计划项目(2016JY0194);中西医结合防治慢性肾疾病(17TD0046)

摘　　要：IgA肾病(IgA nephropathy,IgAN)是我国最常见的原发性肾小球肾炎,也是终末期肾脏病的主要原因,其临床表现多样,病情变化轻重不一,大多数患者病情预后不良。但其发病机制至今尚未完全阐明,治疗手段也十分有限,临床上多以对症治疗为主。目前对IgAN的诊断和病情进展评估缺乏特异性生物标志物,主要依靠肾活检这个金标准,但是肾活检是一项有创检查,对患者有一定的伤害且不便反复操作来监测病情进展,容易导致延迟诊断。因此,寻找与IgAN早期诊断、进展和预后相关的新的生物标志物和有效的治疗靶点尤为重要。IgA nephropathy(IgAN)is the most common type of primary glomerulonephritis in China and is also the main cause of end-stage renal disease.It has various clinical manifestations and different severities,and most patients have poor prognosis.However,the pathogenesis of IgAN remains unclear,and it has limited treatment methods in clinical practice,with symptomatic treatment as the most commonly used method.At present,there are no specific biomarkers for the diagnosis and progression of IgAN,and renal biopsy remains the gold standard;however,renal biopsy is an invasive examination and causes certain damage to patients,and thus it cannot be performed repeatedly to monitor the progression of the disease,which may lead to delayed diagnosis.Therefore,it is of vital importance to find new biomarkers and effective therapeutic targets associated with the early diagnosis,progression,and prognosis for IgAN.

关 键 词：IGAN 生物标志物 靶向性治疗 

分 类 号：R256.5[医药卫生—中医内科学]